Skip to main content
. 2021 Jan 12;13:307–317. doi: 10.2147/CMAR.S287128

Table 1.

The Demographic and Clinical Characteristics of Patients

Characteristics Training Cohort (n=253) Validation Cohort (n=163) P value
Age, years 0.871
 Median [range] 61 [38, 85] 64 [44, 85]
Sex, no. (%) 0.382
 Male 206/253(81.4%) 127/163 (77.9%)
 Female 47/253(18.6%) 36/163 (22.1%)
Smoking, no. (%) 0.354
 Yes 186/253 (73.5%) 113/163 (69.3%)
 No 67/253 (26.5%) 50/163 (30.7%)
Site, no. (%) 0.089
 LUL 64/253 (25.3%) 43/163 (26.4%)
 LLL 65/253 (25.7%) 54/163 (33.1%)
 RUL 65/253 (25.7%) 22/163 (13.5%)
 RML 7/253 (2.8%) 5/163 (3.1%)
 RLL 52/253 (20.5%) 39/163 (23.9%)
Location, no, (%) 0.815
 Central 115/253 (45.5%) 76/163 (46.6%)
 Peripheral 138/253 (54.5%) 87/163 (53.4%)
GTV (cm3) 0.809
 I 15.63 [4.35–51.23] 14.32 [2.85–49.89]
 II 50.14 [13.88–145.18] 43.75 [15.83–186.45]
 III 109.33 [34.95–361.61] 115.43 [33.58–428.33]
AJCC stage*, no, (%) 0.974
 IA 39/253 (15.4%) 24/163 (14.7%)
 IB 46/253 (18.2%) 31/163 (19.0%)
 IIA 31/253 (12.2%) 20/163 (12.3%)
 IIB 26/253 (10.3%) 16/163 (9.8%)
 IIIA 50/253 (19.8%) 33/163 (20.3%)
 IIIB 61/253 (24.1%) 39/163 (23.9%)
T stage*, no, (%) 0.106
 1a 29/253 (11.5%) 15/163 (9.2%)
 1b 25/253 (9.9%) 15/163 (9.2%)
 2a 90/253 (35.6%) 48/163 (29.4%)
 2b 31/253 (12.2%) 21/163 (12.9%)
 3 46/253 (18.2%) 41/163 (25.2%)
 4 32/253 (12.6%) 23/163 (14.1%)
N stage, no, (%) 0.839
 0 112/253 (44.3%) 65/163 (39.9%)
 1 46/253 (18.2%) 39/163 (23.9%)
 2 54/253 (21.3%) 36/163 (22.1%)
 3 41/253 (16.2%) 23/163 (14.1%)

Note: Age and Volume are represented as median and ranges.

Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; AJCC stage*, AJCC stage subgroup; T state*, the T stage subgroup; LUL, left upper lobe; LLL, left lower lobe; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe.